Syneos Health [SYENS] vs Tessenderlo Group NV [TESB] Detailed Stock Comparison
Syneos Health
Euronext
Loading...
Tessenderlo Group NV
Euronext
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Syneos Health wins in 9 metrics, Tessenderlo Group NV wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Syneos Health | Tessenderlo Group NV | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 377.86 | 37.21 | Tessenderlo Group NV |
| Price-to-Book Ratio | 1.19 | 0.86 | Tessenderlo Group NV |
| Debt-to-Equity Ratio | 45.57 | 14.34 | Tessenderlo Group NV |
| PEG Ratio | 5.04 | 14.26 | Syneos Health |
| EV/EBITDA | 7.70 | 5.94 | Tessenderlo Group NV |
| Profit Margin (TTM) | -1.30% | -0.99% | Tessenderlo Group NV |
| Operating Margin (TTM) | 10.86% | 3.44% | Syneos Health |
| EBITDA Margin (TTM) | 10.86% | 3.44% | Syneos Health |
| Return on Equity | -1.20% | -1.40% | Syneos Health |
| Return on Assets (TTM) | 3.16% | 0.87% | Syneos Health |
| Free Cash Flow (TTM) | $217.00M | $152.60M | Syneos Health |
| Dividend Yield | N/A | 2.92% | N/A |
| 1-Year Return | -14.86% | 0.39% | Tessenderlo Group NV |
| Price-to-Sales Ratio (TTM) | 1.10 | 0.57 | Tessenderlo Group NV |
| Enterprise Value | $9.15B | $1.58B | Syneos Health |
| EV/Revenue Ratio | 1.37 | 0.57 | Tessenderlo Group NV |
| Gross Profit Margin (TTM) | 30.87% | 17.68% | Syneos Health |
| Revenue per Share (TTM) | $64 | $45 | Syneos Health |
| Earnings per Share (Diluted) | $-0.81 | $-0.43 | Tessenderlo Group NV |
| Beta (Stock Volatility) | N/A | 0.40 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Syneos Health vs Tessenderlo Group NV Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Syneos Health | 0.09% | -5.49% | -12.32% | 1.44% | 1.92% | -3.49% |
| Tessenderlo Group NV | 0.98% | 0.39% | -6.20% | 2.80% | 11.26% | 33.58% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Syneos Health | -14.86% | -28.28% | -28.28% | -28.28% | -28.28% | -28.28% |
| Tessenderlo Group NV | 0.39% | -14.62% | -20.19% | -2.50% | 16.29% | 16.29% |
News Based Sentiment: Syneos Health vs Tessenderlo Group NV
Syneos Health
News based Sentiment: NEUTRAL
September was a pivotal month marked by a major corporate event – the acquisition of Syneos Health and the subsequent emergence of Syensqo SA/NV. While the acquisition impacts former Syneos Health investors, Syensqo is actively building its profile through share buybacks, product innovation, and a positive analyst outlook, creating a neutral overall investment story.
Tessenderlo Group NV
News based Sentiment: MIXED
September brought both positive signals – strong year-to-date stock performance and an undervaluation according to DCF analysis – and concerning developments like a board resignation and a significant decline in net profit. This creates a mixed investment picture requiring careful monitoring of profitability and leadership changes.
Performance & Financial Health Analysis: Syneos Health vs Tessenderlo Group NV
| Metric | SYENS | TESB |
|---|---|---|
| Market Information | ||
| Market Cap | €7.38B | €1.54B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 136,607 | 17,245 |
| 90 Day Avg. Volume | 126,951 | 18,022 |
| Last Close | €67.78 | €25.70 |
| 52 Week Range | €53.70 - €84.85 | €18.56 - €27.85 |
| % from 52W High | -20.12% | -7.72% |
| All-Time High | €109.90 (Dec 11, 2023) | €41.90 (Oct 30, 2017) |
| % from All-Time High | -38.33% | -38.66% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.08% | 0.07% |
| Quarterly Earnings Growth | 0.72% | -0.31% |
| Financial Health | ||
| Profit Margin (TTM) | -0.01% | -0.01% |
| Operating Margin (TTM) | 0.11% | 0.03% |
| Return on Equity (TTM) | -0.01% | -0.01% |
| Debt to Equity (MRQ) | 45.57 | 14.34 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €60.47 | €30.09 |
| Cash per Share (MRQ) | €12.85 | €3.99 |
| Operating Cash Flow (TTM) | €749.00M | €288.60M |
| Levered Free Cash Flow (TTM) | €451.50M | €167.60M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 2.92% |
| Last 12-Month Dividend | N/A | €0.75 |
Valuation & Enterprise Metrics Analysis: Syneos Health vs Tessenderlo Group NV
| Metric | SYENS | TESB |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 377.86 | 37.21 |
| Forward P/E | 9.65 | 14.26 |
| PEG Ratio | 5.04 | 14.26 |
| Price to Sales (TTM) | 1.10 | 0.57 |
| Price to Book (MRQ) | 1.19 | 0.86 |
| Market Capitalization | ||
| Market Capitalization | €7.38B | €1.54B |
| Enterprise Value | €9.15B | €1.58B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.37 | 0.57 |
| Enterprise to EBITDA | 7.70 | 5.94 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.40 |
| Book Value per Share (MRQ) | €60.47 | €30.09 |
Financial Statements Comparison: Syneos Health vs Tessenderlo Group NV
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SYENS | TESB |
|---|---|---|
| Revenue/Sales | €1.68B | €346.10M |
| Cost of Goods Sold | €1.16B | €284.90M |
| Gross Profit | €514.00M | €61.20M |
| Research & Development | €78.00M | N/A |
| Operating Income (EBIT) | €147.00M | €3.10M |
| EBITDA | €306.00M | €-53.40M |
| Pre-Tax Income | €29.00M | €-16.70M |
| Income Tax | €27.00M | €1.10M |
| Net Income (Profit) | €2.00M | €-17.80M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SYENS | TESB |
|---|---|---|
| Cash & Equivalents | €579.00M | €182.40M |
| Total Current Assets | €3.28B | €1.27B |
| Total Current Liabilities | €2.07B | €599.70M |
| Long-Term Debt | €1.77B | €134.10M |
| Total Shareholders Equity | €7.27B | €1.91B |
| Retained Earnings | €4.77B | N/A |
| Property, Plant & Equipment | €3.85B | €704.50M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SYENS | TESB |
|---|---|---|
| Operating Cash Flow | €40.00M | €15.30M |
| Capital Expenditures | €-143.00M | €-22.70M |
| Free Cash Flow | €9.00M | €-12.90M |
| Debt Repayment | €-166.00M | €43.70M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SYENS | TESB |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 136,607 | 17,245 |
| Average Daily Volume (90 Day) | 126,951 | 18,022 |
| Shares Outstanding | 103.45M | 60.49M |
| Float Shares | 69.83M | 18.66M |
| % Held by Insiders | 0.31% | 0.67% |
| % Held by Institutions | 0.28% | 0.06% |
Dividend Analysis & Yield Comparison: Syneos Health vs Tessenderlo Group NV
| Metric | SYENS | TESB |
|---|---|---|
| Last 12-Month Dividend | N/A | €0.75 |
| Last 12-Month Dividend Yield | N/A | 2.92% |
| 3-Year Avg Annual Dividend | N/A | €0.75 |
| 3-Year Avg Dividend Yield | N/A | 2.85% |
| 3-Year Total Dividends | N/A | €2.25 |
| Ex-Dividend Date | N/A | Jun 04, 2025 |